Group 1 - The MSCI China Healthcare Index has increased by 62.8% from the beginning of 2025 to November 21, outperforming the MSCI China Index by 32.2% [1] - The recent pullback in the pharmaceutical sector, with the MSCI China Healthcare Index declining by 8% from early October to November 21, is attributed to profit-taking by investors and high valuations of some innovative drug companies [1] - Despite the significant recovery in industry valuations, the pharmaceutical sector is expected to face challenges in achieving widespread growth in 2026, although there are opportunities for valuation and performance recovery in specific stocks such as medical services, pharmaceuticals, and CXO companies [1] Group 2 - As of October 2025, the upfront payments for Chinese innovative drug license-out transactions have reached $6.3 billion, a 53% year-over-year increase, surpassing the total for 2024 [2] - The interest from multinational corporations (MNCs) in Chinese innovative pipelines has increased, with 20% of the number and 39% of the value of top MNC's transactions in China occurring in the first nine months of 2025 [2] - The trend of Chinese innovative drugs going abroad is expected to continue into 2026, with a focus on the overseas clinical advancement of authorized pipelines due to higher certainty and potential for stock price catalysts [2] Group 3 - The demand for pharmaceutical research and development has begun to recover in 2025, with a 444% year-over-year increase in financing for Chinese innovative drugs in Q3 2025 [3] - Global innovative drug financing also showed positive growth in Q3 2025, increasing by 8.6% [3] - Chinese CXO companies, deeply involved in the global pharmaceutical R&D supply chain, are experiencing growth in global demand, as evidenced by WuXi AppTec's orders increasing by 41.2% year-over-year as of September 30 [3] Group 4 - The acceleration of centralized procurement for medical devices has continued in 2023, leading to significant performance differentiation across various segments [4] - In high-value consumables, the impact of centralized procurement is diminishing, with orthopedics entering a "post-procurement" recovery phase [4] - The medical device sector is experiencing a temporary high demand driven by equipment updates, with a 30% year-over-year increase in the bidding market for Q3 2025 [4] - The in vitro diagnostics (IVD) market is facing challenges due to centralized procurement and cost control measures, resulting in a year-over-year decline of 5% in the domestic IVD market in the first half of 2025 [4]

Core Viewpoint - The release of the 2025 version of the basic medical insurance directory and the first commercial insurance directory is expected to support innovation in the CXO industry, leading to a potential performance recovery in the second half of the year [1] Summary by Categories Industry Outlook - The report indicates that several companies' core innovative products have been included in the medical insurance directory [1] - Despite ongoing pressures on medical insurance revenue due to macroeconomic conditions and aging populations, attention is drawn to the renewal of national centralized procurement [1] Commercial Insurance - The initial commercial insurance directory is expected to have limited short-term impact on product sales due to the small scale of commercial insurance [1] - However, the significance of the commercial insurance directory is highlighted as it may pave the way for the expansion of commercial medical insurance in China, marking the beginning of a diversified payment system development [1] Company Recommendations - The report recommends buying shares in the following companies: - Sanofi (01530) - Genscript Biotech (02273) - WuXi AppTec (02268) - Genor Biopharma (02367) - Innovent Biologics (01801) - China Biologic Products (01177) [1]

Core Viewpoint - The pharmaceutical and biotechnology sector has demonstrated resilience and growth potential in 2023, driven by policy support and industry transformation, leading to a high-quality development phase characterized by innovation and cost control [1][4]. Industry Performance - As of December 8, 2023, the pharmaceutical and biotechnology sector has shown a weighted average increase of 30.64% in market capitalization, ranking 14th among 31 primary industries, but underperforming the CSI 300 index by 3.82 percentage points [2]. - The sector has exhibited significant internal differentiation, with innovation-driven segments outperforming others; for instance, other biological products, chemical preparations, and medical R&D outsourcing saw increases of 57.07%, 54.68%, and 51.87% respectively, while traditional Chinese medicine, vaccines, and blood products lagged behind with increases of only 3.89%, -0.73%, and -10.85% [2]. Market Dynamics - The strong performance of the innovative drug industry chain is attributed to four key factors: exceeding expectations in earnings from leading companies like BeiGene and WuXi AppTec, ongoing supportive policies for innovative drugs and devices, increased activity in domestic innovative drug business development (BD) transactions, and substantial clinical data disclosures at major global conferences [2][4]. Recent Adjustments - Since September 2023, the sector has experienced a temporary pullback, with a maximum drawdown of 12.72% from September 1 to November 21, primarily due to prior gains, unmet expectations in BD transactions, and geopolitical disturbances [3]. Valuation Insights - As of December 8, 2023, the sector's price-to-earnings (P/E) ratio stands at 51.75, with a premium of 267.54% over the CSI 300 index and 63.87% over all A-shares (excluding banks), indicating a relatively high valuation compared to historical levels [3]. Policy Support - The "14th Five-Year Plan" emphasizes support for innovative drugs and medical devices, transitioning from process optimization to comprehensive empowerment across the industry chain, with a focus on key technological breakthroughs in areas like dual antibodies, ADCs, and mRNA [6]. Investment Opportunities - Three main investment themes are highlighted: 1. The innovative drug sector, which is expected to thrive due to policy support and market expansion [7]. 2. The CXO sector, benefiting from increased demand for innovative drug development [7]. 3. Consumer healthcare, which is anticipated to recover as consumption policies promote growth [7]. Technological Integration - The integration of AI technologies into the biopharmaceutical industry is expected to enhance research efficiency and product development, with significant growth potential in AI-driven medical diagnostics and treatment processes [8].

Core Viewpoint - The pharmaceutical and biotechnology sector has shown resilience and growth potential in 2023, driven by policy support and industry transformation, with a clear focus on innovation and cost control shaping the industry landscape [1][5]. Industry Performance - The pharmaceutical and biotechnology sector has achieved a weighted average increase of 30.64% in market capitalization as of December 8, 2023, ranking 14th among 31 primary industries, but underperforming the CSI 300 index by 3.82 percentage points [1]. - The sector has exhibited significant internal differentiation, with innovation-driven segments outperforming others, such as biopharmaceuticals and medical R&D outsourcing, which saw increases of 57.07%, 54.68%, and 51.87% respectively, while traditional segments like traditional Chinese medicine and vaccines lagged behind [2]. Key Factors for Growth - The strong performance of the innovative drug industry chain is attributed to four core factors: exceeding expectations in earnings from leading companies like BeiGene and WuXi AppTec, continuous implementation of supportive policies, increased activity in domestic innovative drug business development (BD) transactions, and substantial clinical data disclosures at global academic conferences [2][3]. Financial Metrics - For the first three quarters of 2023, the pharmaceutical and biotechnology sector reported total revenue of 18,461.96 billion yuan, a year-on-year decrease of 1.27%, while net profit attributable to shareholders was 1,410.97 billion yuan, down 1.63%. However, the third quarter showed signs of recovery with a revenue increase of 1.21% and a net profit increase of 3.79% [4]. Policy Support - The "14th Five-Year Plan" emphasizes support for innovative drugs and medical devices, transitioning from process optimization to comprehensive empowerment across the industry chain, with a focus on key technological breakthroughs in areas such as dual antibodies, ADCs, and digital medicine [5]. Investment Opportunities - Three main investment themes are highlighted: 1. The innovative drug sector, which is expected to be the strongest investment theme due to policy support and market expansion [6]. 2. The CXO sector, benefiting from improved demand for innovative drug development and showing significant performance improvements [6]. 3. Consumer healthcare companies, which are anticipated to see a recovery in demand and performance due to supportive policies [6]. Technological Integration - The integration of AI technology into the biopharmaceutical industry is expected to enhance research efficiency and product development, with AI applications improving diagnostic processes and overall healthcare delivery [7].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]

Investment Rating - The report rates multiple companies in the healthcare sector as "Outperform," including BeiGene, China Resources Pharmaceutical, JD Health, Innovent Biologics, WuXi Biologics, and many others [1]. Core Insights - The Hong Kong healthcare sector has shown resilience, with the Hang Seng Healthcare Index gaining 72.2% year-to-date, outperforming the Hang Seng Index by 41.1 percentage points [4][28]. - The implementation of the "dual catalogs" for basic medical insurance and commercial insurance is expected to support innovation in the pharmaceutical sector, with 114 new drugs added to the basic medical insurance catalog and a success rate of 88% [5][30]. - The report highlights the strong performance of the pharmaceutical distribution and CXO sectors, with respective gains of 2.0% and 1.7% in the past week [15][29]. Summary by Sections Market Performance - The Hang Seng Healthcare Index fell by 0.7% in the week of December 1-5, 2025, underperforming the Hang Seng Index by 1.6 percentage points [4][28]. - The pharmaceutical distribution sector and CXO services performed well, with increases of 2.0% and 1.7%, respectively [15][29]. Drug Catalog Implementation - The "National Basic Medical Insurance Catalog" and the first edition of the "Commercial Insurance Innovative Drug Catalog" were released, with 114 new drugs added to the basic insurance catalog [5][30]. - The commercial insurance catalog includes 19 innovative drugs, emphasizing support for innovation and addressing the needs of the elderly and children [13][30]. Company Highlights - Notable companies that performed well include Jinxin Fertility (+7.5%), Harbour BioMed-B (+5.3%), and WuXi Biologics (+4.7%) [15][29]. - The report suggests increasing focus on companies with strong performance certainty in the CXO sector and those with stable long-term demand in medical services [15][29].

Investment Rating - The report maintains an investment rating of "Positive" for the pharmaceutical and biotechnology industry [2]. Core Viewpoints - The recent release of the "Medical Insurance + Commercial Insurance Dual Directory" by the National Medical Insurance Administration is expected to boost investment enthusiasm for innovative drugs. The report suggests focusing on investment opportunities in innovative drugs, CXO, and the upstream life sciences industry chain [3][9]. - The pharmaceutical sector is currently experiencing a lack of clear market direction, with the pharmaceutical commercial sector leading in performance. Notable stocks include Haiwang Biological (up 55.59%), Ruikang Pharmaceutical (up 36.54%), and Yue Wannianqing (up 15.37%) [3][9]. - The report emphasizes the importance of companies with stable dividends and operational improvements, as well as potential turning points in high-end medical devices [3][11]. Summary by Sections 1. Market Performance - The pharmaceutical and biotechnology sector's return was -0.74% last week, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices. The pharmaceutical commercial sector had the highest weekly return at 5.19% [3][7]. - Over the past month, the sector's return was -2.35%, also ranking 20th among sub-industry indices, with the pharmaceutical commercial sector leading at 5.78% [3][7]. 2. Innovative Drugs - The report recommends focusing on companies with leading product pipelines and market potential, including Innovent Biologics, 3SBio, Hengrui Medicine, and others [3][9][10]. 3. CXO and Upstream Life Sciences - Key CXO companies to watch include WuXi AppTec, WuXi Biologics, and others. The report also highlights clinical CRO leaders and resource-based CXOs [10]. 4. High-End Medical Devices - The report identifies several companies in the high-end medical device sector that may benefit from market recovery and increased demand, including Mindray Medical and others [11]. 5. Valuation Metrics - The current PE (TTM) for the pharmaceutical and biotechnology industry is 29.27 times, which is below the historical average of 30.88 times over the past five years [12][15].

招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 行业及公司点评 全球市场观察 2025 年 12 月 8 日 1 中国股市上涨，港股原材料、金融与工业领涨，综合、公用事业与必选消费 下跌，南向净买入 13.4 亿港元，小米与美团净买入最多，阿里与腾讯净卖出 居前。A 股非银金融、有色金属与工贸综合涨幅居前，银行、煤炭与电信服 务跑输市场。A 股券商板块大涨，中国证监会主席表示鼓励头部机构通过并 购重组打造国际一流投行，将对优质券商适度松绑打开资本空间与杠杆限制， 鼓励中小机构打造小而美的精品投行、特色投行和特色服务商；保险板块大 涨，保险公司投资资本市场的风险因子再度下调，显示监管机构鼓励险资等 长期资本入市的态度。 美股上涨，通讯服务、信息技术与可选消费涨幅居前，公用事业、能源与医 疗保健跌幅最大。戴尔、联想、惠普等主要 OEM 厂商计划大幅提高服务器 价格，因供应很难跟上快速增长的需求。微软与博通商谈定制芯片设计合作， 可能替换现有供应商 Marvell，以降低对英伟达依赖。随着 AI 产品创新，定 制芯片需求激增，科技公司寻求供应链多元化以降低风险与成本。 美债收益率升至两周新高，美元指数转 ...

Group 1 - The Hang Seng Index opened down 0.07%, while the Hang Seng Tech Index rose by 0.08%. Notably, tech stocks were active, with Baidu increasing by 3.29% as the company evaluates the potential spin-off and listing of Kunlun Chip, although it does not guarantee that the spin-off and listing will occur [1] - Guoyuan International suggests that the direction of the Federal Reserve's decision in December remains uncertain ahead of the release of some recent economic data. The hawkish tone from the Bank of Japan may lead to short-term external disturbances for the Hong Kong stock market. However, the overall valuation level of the Hong Kong market is supported by the Fed's dovish shift and the restoration of dollar liquidity following the reopening of the U.S. government [1] - According to CMB International, the pharmaceutical industry is expected to undergo a critical turning point in 2025. The firm anticipates a stable and positive trend for the sector in 2026, although core factors affecting market performance may show divergence. Short-term focus should be on overseas transactions and performance in innovative drugs, while the CXO sector should be monitored for industry consolidation trends after a bottom reversal [1] Group 2 - Guotai Junan Securities believes that the recent adjustment in the Hong Kong stock market opens up space for an upward trend in 2026. In November, net inflows from southbound funds into the Hong Kong market exceeded 110 billion RMB, indicating strong liquidity and a willingness to accumulate stocks at lower levels [2] - The firm predicts that the Hong Kong stock market could operate between 30,000 and 32,000 points in 2026, reflecting a positive outlook for the market [2]